7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 
      
    		                          
      assets
    		                          
      current assets:
    		                          
      cash and cash equivalents
    		642,951,000 748,953,000 540,599,000 681,101,000 266,324,000 407,958,000 475,222,000 375,935,000 505,213,000 302,438,000 407,368,000 376,689,000 483,235,000 470,098,000 371,550,000 393,772,000 180,347,000 378,420,000 471,176,000 356,082,000 366,967,000 540,919,000 757,049,000 363,773,000 413,973,000 293,803,000 
      marketable securities
    		2,991,000 7,939,000    39,813,000 44,469,000   30,869,000 34,122,000 51,580,000 75,080,000 218,466,000 261,904,000            
      accounts receivable
    		116,518,000 76,868,000 115,265,000 4,722,000              1,213,000         
      inventories
    		24,527,000 18,277,000 3,954,000                        
      prepaid expenses and other current assets
    		52,395,000 60,240,000 35,355,000 34,743,000 38,367,000 28,396,000 28,108,000 24,305,000 22,583,000 20,546,000 25,145,000 21,922,000 25,661,000 32,754,000 34,021,000 32,446,000 31,927,000 26,670,000 25,534,000 35,731,000 26,703,000 20,996,000 19,782,000 22,629,000 22,102,000 12,906,000 
      total current assets
    		839,382,000 912,277,000 695,173,000 720,692,000 444,578,000 616,236,000 783,424,000 477,593,000 587,670,000 432,884,000 552,702,000 548,853,000 642,219,000 771,280,000 716,230,000 888,858,000 639,710,000 909,871,000 945,114,000 642,824,000 745,384,000 861,935,000 924,957,000 568,622,000 558,155,000 306,709,000 
      investment in nonconsolidated entities
    		92,168,000 108,002,000 128,191,000 143,747,000 160,443,000                      
      property and equipment
    		5,830,000 6,107,000 6,698,000 7,011,000 8,701,000 9,840,000 11,414,000 11,816,000 12,413,000 13,047,000 13,566,000 14,569,000 15,603,000 16,873,000 17,182,000 30,066,000 27,741,000 26,272,000 22,816,000 20,325,000 16,182,000 15,573,000 15,755,000 5,625,000 2,984,000 1,865,000 
      operating lease right-of-use assets
    		6,553,000 6,186,000 7,166,000 5,767,000 6,439,000 7,267,000 8,052,000 8,027,000 9,332,000 9,814,000 10,532,000 10,678,000 11,738,000 12,850,000 13,936,000 15,907,000 17,108,000 15,964,000 12,997,000 16,508,000 9,644,000 10,465,000 8,855,000    
      intangible assets
    		28,795,000 29,513,000 27,802,000 23,926,000 24,525,000 25,123,000 25,721,000 26,319,000 26,917,000 27,515,000 28,113,000 28,712,000 29,310,000 29,908,000 30,476,000 44,934,000 46,204,000          
      other assets
    		25,522,000 18,105,000 16,608,000 18,195,000 20,291,000 18,903,000 20,722,000 22,625,000 18,676,000 20,401,000 20,767,000 20,224,000 29,870,000 31,322,000 35,325,000 33,027,000 33,054,000 49,797,000 30,179,000 23,931,000 16,483,000 17,254,000 17,022,000 26,288,000 2,598,000 9,471,000 
      total assets
    		998,250,000 1,080,190,000 881,638,000 919,338,000 664,977,000 794,375,000 849,333,000 546,380,000 655,008,000 503,661,000 625,680,000 623,036,000 728,740,000 862,233,000 813,149,000 1,012,792,000 781,524,000 1,081,486,000 1,093,308,000 703,588,000 787,693,000 905,227,000 989,799,000 631,679,000 640,530,000 325,540,000 
      liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit
    		                          
      current liabilities:
    		                          
      accounts payable
    		18,702,000 26,134,000 27,525,000 9,618,000 13,363,000 18,126,000 4,728,000 10,655,000 4,472,000 3,874,000 4,076,000 11,558,000 10,158,000 8,793,000 10,107,000 11,884,000 12,035,000 22,329,000 10,340,000 8,945,000 9,839,000 12,835,000 13,086,000 8,852,000 10,270,000 16,065,000 
      accrued compensation and benefits
    		56,155,000 37,187,000 33,447,000 58,329,000 43,541,000 29,056,000 32,395,000 57,370,000 33,735,000 28,690,000 18,869,000 31,256,000 24,842,000 32,609,000 15,458,000 37,041,000 21,560,000 21,865,000 20,741,000 29,682,000 18,755,000 13,590,000 5,647,000 13,317,000 7,580,000 4,736,000 
      accrued research and development liabilities
    		34,619,000 31,295,000 33,630,000 34,272,000 40,997,000 33,178,000 40,933,000 29,765,000 29,244,000 28,298,000 37,064,000 39,803,000 44,564,000 50,091,000 43,342,000 44,138,000 37,645,000 55,620,000 33,423,000 27,290,000 24,901,000 37,241,000 29,522,000 20,896,000 13,198,000 9,419,000 
      operating lease liabilities, current portion
    		5,294,000 4,782,000 5,209,000 4,506,000 4,600,000 4,623,000 4,544,000 4,128,000 4,137,000 3,776,000 3,674,000 3,675,000 4,044,000 4,310,000 4,363,000 4,938,000 4,999,000 4,540,000 3,807,000 3,795,000 3,617,000 3,627,000 2,510,000    
      deferred revenue, current portion
    		9,087,000 10,540,000 11,620,000 14,604,000 11,771,000 15,098,000 13,957,000 6,096,000 6,592,000 6,210,000 6,675,000 8,156,000 7,518,000 7,190,000             
      other current liabilities
    		92,743,000 65,916,000 40,674,000                        
      total current liabilities
    		216,600,000 175,854,000 152,105,000 154,400,000 139,216,000 134,364,000 141,477,000 143,844,000 106,065,000 110,120,000 96,596,000 121,428,000 119,194,000 141,160,000 103,463,000 135,069,000 95,823,000 131,909,000 94,729,000 95,648,000 75,707,000 92,640,000 64,914,000 60,385,000 39,858,000 38,705,000 
      2031 notes
    		564,087,000 563,597,000 563,124,000                        
      2029 notes
    		740,380,000 739,874,000 739,372,000 738,872,000 738,376,000 737,882,000 737,392,000 736,905,000 736,422,000 735,940,000 735,463,000 734,988,000 734,516,000 734,047,000 733,581,000 733,119,000 732,659,000 732,202,000 731,747,000        
      2027 notes
    		546,549,000 546,088,000 545,628,000 545,173,000 544,719,000 544,270,000 543,823,000 543,379,000 542,938,000 542,501,000 542,065,000 541,634,000 541,205,000 540,779,000 540,355,000 539,934,000 539,517,000 539,102,000 538,690,000 383,436,000 378,502,000 373,651,000 368,923,000    
      term loan
    		   437,337,000 436,221,000 435,447,000 434,717,000 446,445,000 441,721,000 440,496,000 435,764,000 430,993,000 422,972,000 418,353,000 434,114,000            
      deferred royalty obligations
    		836,126,000 813,959,000                         
      operating lease liabilities, net of current portion
    		3,427,000 4,025,000 4,915,000 4,696,000 5,833,000 7,059,000 8,297,000 8,981,000 9,812,000 10,916,000 11,904,000 12,274,000 13,000,000 14,276,000 15,494,000 17,428,000 18,683,000 18,022,000 13,862,000 14,677,000 8,236,000 9,117,000 8,678,000    
      deferred revenue, net of current portion
    		13,131,000 14,667,000 17,508,000 17,095,000 18,627,000 16,961,000 19,890,000                    
      other long-term liabilities
    		679,000 545,000 352,000 286,000 377,000 485,000 595,000 9,361,000 11,785,000 13,326,000 17,501,000 26,643,000 28,226,000 28,631,000 26,829,000 22,069,000 27,578,000          
      total liabilities
    		2,920,979,000 2,858,609,000 2,520,303,000 2,376,950,000 1,883,369,000 1,876,468,000 1,886,191,000 1,888,915,000 1,848,743,000 1,853,299,000 1,839,293,000 1,867,960,000 1,859,113,000 1,877,246,000 1,853,836,000 1,878,371,000 1,517,398,000 1,537,111,000 1,481,402,000 595,702,000 569,306,000 577,715,000 537,728,000 155,703,000 116,263,000 114,049,000 
      commitments and contingencies
    		                          
      redeemable convertible noncontrolling interests
    		23,000 -445,000 -227,000 142,000 645,000 -223,000 525,000 478,000 1,403,000 333,000 -204,000 -1,589,000 -2,388,000 -1,499,000 336,000 1,423,000 2,967,000 1,865,000 1,271,000 1,630,000 2,574,000 1,906,000 3,053,000 2,243,000 2,570,000 175,000 
      stockholders’ deficit:
    		                          
      undesignated preferred stock, 0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
    		                          
      common stock
    		200,000 198,000 197,000 196,000 195,000 194,000 193,000 181,000 180,000 168,000 167,000 157,000 156,000 154,000 154,000 154,000 153,000 153,000 152,000 125,000 125,000 125,000 124,000 124,000 117,000  
      treasury stock
    		-323,276,000 -323,276,000 -323,276,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -130,308,000 -125,000,000 -75,000,000 -75,000,000 -75,000,000 -75,000,000    
      additional paid-in capital
    		2,018,335,000 1,980,805,000 1,938,369,000 1,903,155,000 1,876,091,000 1,851,058,000 1,820,994,000 1,481,032,000 1,459,596,000 1,128,100,000 1,106,635,000 938,703,000 917,333,000 892,960,000 867,596,000 841,530,000 821,220,000 799,679,000 767,117,000 1,021,344,000 1,006,944,000 992,691,000 986,746,000 848,107,000 826,062,000  
      accumulated other comprehensive income
    		2,000 1,000  8,000 5,000 -4,000 2,000 31,000 34,000 63,000      -132,000 19,000 36,000 -57,000 192,000 461,000 858,000 726,000 254,000 152,000  
      accumulated deficit
    		-3,628,331,000 -3,445,588,000 -3,263,685,000 -3,096,263,000 -2,831,213,000 -2,669,173,000 -2,595,717,000 -2,560,501,000 -2,392,353,000 -2,215,354,000 -2,057,455,000 -1,918,149,000 -1,780,558,000 -1,643,219,000 -1,633,363,000 -1,436,966,000 -1,289,789,000 -1,133,854,000 -1,037,506,000 -888,755,000 -768,774,000 -652,915,000 -531,881,000 -440,031,000 -366,573,000 -326,068,000 
      total bridgebio stockholders’ deficit
    		-1,933,070,000 -1,787,860,000 -1,648,395,000 -1,467,904,000 -1,229,922,000 -1,092,925,000 -1,049,528,000 -1,354,257,000 -1,207,543,000 -1,362,023,000 -1,225,665,000 -1,254,617,000 -1,138,417,000 -1,025,532,000 -1,040,996,000            
      noncontrolling interests
    		10,318,000 9,886,000 9,957,000 10,150,000 10,885,000 11,055,000 12,145,000 11,244,000 12,405,000 12,052,000 12,256,000 11,282,000 10,432,000 12,018,000 -27,000 3,412,000 4,556,000 6,804,000 5,929,000 48,350,000 52,057,000 59,847,000 68,303,000 65,279,000 61,939,000 48,391,000 
      total stockholders’ deficit
    		-1,922,752,000 -1,777,974,000 -1,638,438,000 -1,457,754,000 -1,219,037,000 -1,081,870,000 -1,037,383,000 -1,343,013,000 -1,195,138,000 -1,349,971,000 -1,213,409,000 -1,243,335,000 -1,127,985,000 -1,013,514,000 -1,041,023,000            
      total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit
    		998,250,000 1,080,190,000 881,638,000 919,338,000 664,977,000 794,375,000 849,333,000 546,380,000 655,008,000 503,661,000 625,680,000 623,036,000 728,740,000 862,233,000 813,149,000            
      deferred royalty obligation
    		  497,299,000 479,091,000                       
      investments in equity securities
    		                          
      restricted cash
    		   126,000 139,409,000 139,409,000 131,000 16,653,000 16,652,000 19,930,000 25,503,000 37,930,000               
      accrued professional and other accrued liabilities
    		   33,071,000 24,944,000 34,283,000 44,920,000 35,830,000 27,885,000 39,272,000                 
      receivables from licensing and collaboration agreements
    		    478,000 660,000 235,494,000                    
      investment in nonconsolidated entity
    		     117,006,000                     
      investment in equity securities
    		       58,949,000 38,052,000 50,487,000 49,803,000 43,653,000 33,662,000 27,141,000 37,772,000 49,148,000 17,707,000 18,894,000         
      receivable from licensing and collaboration agreements
    		       1,751,000 5,170,000 8,614,000 10,761,000 17,079,000 24,581,000 22,821,000 10,983,000 19,749,000 7,710,000 35,363,000         
      accrued professional services
    		          4,015,000 1,790,000 4,230,000 6,183,000 5,411,000 6,786,000 4,976,000 6,378,000 4,518,000 5,579,000 4,706,000 8,609,000 3,145,000 2,222,000   
      other accrued liabilities
    		          22,223,000 25,190,000 23,838,000 31,984,000 24,782,000 30,282,000 14,608,000 21,177,000 18,254,000 13,349,000 8,691,000 11,462,000 7,465,000 3,020,000 4,789,000 4,188,000 
      accumulated other comprehensive loss
    		          -12,000 -328,000 -348,000 -427,000 -383,000            
      short-term marketable securities
    		               393,743,000 419,264,000 459,243,000 447,942,000 251,011,000 343,714,000 300,020,000 148,126,000 182,220,000 122,080,000  
      liabilities, redeemable convertible noncontrolling interests and stockholders’ equity
    		                          
      leo call option liability
    		                   5,550,000 5,198,000 5,276,000 3,539,000 4,078,000 4,021,000 4,297,000 
      term loans, current portion
    		                  3,646,000 1,458,000       
      term loans, net of current portion
    		               430,752,000 103,138,000 102,611,000 90,762,000 92,421,000       
      stockholders’ equity
    		                          
      total bridgebio stockholders’ equity
    		               -870,414,000 -743,397,000 -464,294,000 -395,294,000 57,906,000       
      total stockholders’ equity
    		               -867,002,000 -738,841,000 -457,490,000 -389,365,000 106,256,000       
      total liabilities, redeemable convertible noncontrolling interests and stockholders’ equity
    		               1,012,792,000 781,524,000 1,081,486,000 1,093,308,000 703,588,000 787,693,000 905,227,000 989,799,000 631,679,000 640,530,000  
      receivable from a related party
    		                462,000 8,962,000 462,000  8,000,000      
      long-term marketable securities
    		                 60,688,000 82,202,000    23,210,000 31,144,000 75,886,000  
      other liabilities
    		                 13,265,000 11,612,000 9,520,000 13,469,000 9,399,000 2,797,000 3,527,000 1,388,000 347,000 
      build-to-suit lease obligation
    		                       8,000,000   
      stockholders’ equity:
    		                          
      term loans, noncurrent
    		                    93,392,000 92,908,000 92,416,000 91,791,000 75,017,000 74,997,000 
      total bridgebio stockholders' equity
    		                    163,756,000 265,759,000 380,715,000 408,454,000 459,758,000  
      total stockholders' equity
    		                    215,813,000 325,606,000 449,018,000 473,733,000 521,697,000  
      investments in nonconsolidated entities
    		                          
      accrued distributions to stockholders
    		                          
      undesignated preferred stock, 0.001 par value; 25,000,000 and no shares authorized as of december 31, 2019 and 2018; no shares issued and outstanding as of december 31, 2019 and 2018
    		                          
      pellepharm investment
    		                        907,000 7,495,000 
      undesignated preferred stock, 0.001 par value; 25,000,000 and no shares authorized as of september 30, 2019 and december 31, 2018; no shares issued and outstanding as of september 30, 2019 and december 31, 2018
    		                          
      liabilities, redeemable convertible preferred units, redeemable founder units, redeemable common units, management incentive units, redeemable convertible noncontrolling interests, and members’ deficit
    		                          
      accrued distributions to unitholders
    		                          
      redeemable convertible preferred units
    		                         479,044,000 
      redeemable founder units
    		                         1,754,000 
      redeemable common units
    		                         1,672,000 
      management incentive units
    		                         6,523,000 
      members’ deficit:
    		                          
      total bridgebio members’ deficit
    		                         -326,068,000 
      total members’ deficit
    		                         -277,677,000 
      total liabilities, redeemable convertible preferred units, redeemable founder units, redeemable common units, management incentive units, redeemable convertible noncontrolling interests, and members’ deficit
    		                         325,540,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.